Document is current
Any future updates will be listed below
-
Authors
Petersen, Jonas https://orcid.org/0000-0002-6219-0271
Finan, Brian https://orcid.org/0000-0003-1178-8481
Johansen, Valdemar B. I.
Müller, Timo D. https://orcid.org/0000-0002-0624-9339
Clemmensen, Christoffer https://orcid.org/0000-0003-2456-9667
- License Information
-
More Information
Article History
Accepted: 17 March 2026
First Online: 13 May 2026
Competing interests
: C.C. and J.P. are co-founders of Ousia Pharma, a biotech company developing therapeutics for the treatment of obesity. C.C. and J.P. are co-founders of Heureka Therapetics, a biotech company developing therapeutics for the treatment of metabolic liver disease. C.C. has received speaking fees from Novo Nordisk. B.F. is a shareholder and former employee of Novo Nordisk. B.F. is an employee of Eli Lilly and Company and may hold stock. T.D.M. receives funding from Novo Nordisk and has received speaking fees from Novo Nordisk, Eli Lilly, Boehringer Ingelheim, Merck, AstraZeneca, Mercodia and Berlin Chemie AG. T.D.M. further holds stocks from Novo Nordisk and Eli Lilly. V.B.I.J. declares no competing interests.
